The global superdisintegrants is projected to reach USD 536.5 million by 2023 from USD 366.4 billion in 2018, at a CAGR of 7.9%. Various factors, such as the increasing adoption of orally disintegrating tablets and fast disintegrating tablets, growing generics market, and the emergence of new superdisintegrants for the pharmaceutical industry, are driving the market for superdisintegrants. The shifting focus of pharmaceutical manufacturing to emerging markets and the growth of the overall pharmaceutical sector in these markets present significant opportunities for the superdisintegrants market growth. However, safety and quality concerns are expected to challenge the growth of the superdisintegrants market to a certain extent during the forecast period.
Players in the global superdisintegrants market, such as Ashland Inc. (US), BASF SE (Germany), DowDuPont (US), JRS Pharma (Germany), DFE Pharma (Germany), Roquette Freres (France), Asahi Kasei Corporation (Japan), Merck KGaA (Germany), Corel Pharma Chem (India), and Avantor Performance Materials, LLC (US) are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies of expansions, mergers & acquisitions, agreements, and product launches.
To know about the assumptions considered for the study download the pdf brochure
BASF was the leading player in the superdisintegrants market and accounted for the largest share in 2017. The company offers a well-balanced portfolio for the superdisintegrants market. Its stronghold in the global pharmaceutical excipients market is primarily attributed to its innovative product portfolio and strong relationships with its customers. Additionally, having a large number of production sites gives it a competitive advantage over other players in the excipients market. The company also provides customized products to make customers’ production processes more efficient. To remain competitive in the market, the company focuses on expanding its presence across the globe. It opened Innovation Campus Asia Pacific in India with an initial investment of USD 2.76 million. By 2020, the company plans to conduct around 25% of its global R&D in Asia Pacific.
Ashland was the second-largest market player in the superdisintegrants market in 2017. The company offers crospovidone for the largest superdisintegrants market. Ashland’s prominent position in the market is attributed to its research and development activities, robust manufacturing capabilities, and an extensive distribution network across the world, which enables it to serve customers in over 100 countries. The company’s growth strategy for the pharmaceutical excipients business mainly concentrates on expanding its production capacity and meet the rising customer demand. The company majorly focuses on expansions to grow and maintain its position in the superdisintegrants market. For instance, in October 2016, the company opened a new pharmaceutical excipient facility in Nanjing (China) to produce excipients for the Asian market. Similarly, it invested USD 89 million to expand its specialty chemical production at its manufacturing facility in Virginia (US). The company also focuses on business reconstruction to stabilize its financial growth. In April 2016, Ashland announced its plans to split into two independent, publicly traded companies Ashland Specialty Ingredients and Ashland Valvoline. This move will help the company to reap higher profits and will further strengthen its pharmaceutical excipients and superdisintegrants business.
Superdisintegrants Market by Product (Modified Starch, Modified Cellulose, Crospovidone, Ion Exchange Resin), Formulation (Tablet, Capsules), Therapeutic Area (Gastrointestinal, Cardiovascular, Neurology, Oncology, Hematology) - Global Forecast to 2023
Mr. Shelly Singh
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE